Prolight Diagnostics (PRLD) Q4 2024 earnings summary

Executive summary

• Achieved key technical milestones with delivery of first commercial prototypes of the Psyros point-of-care (POC) system; pre-validation studies underway with results expected Q1 2025.

• Strong market interest in POC diagnostics, supported by recent industry M&A activity and positive feedback from potential partners on Psyros system.

• Strengthened intellectual property with two new European patent approvals for core Psyros technology, enhancing competitive position.

Financial highlights

• Q4 2024: Net sales SEK 0 (0); other operating income SEK 15.3m (11.6m); profit after tax SEK 2.0m (-110.1m); EPS SEK 0.00 (-0.32).

• Full year 2024: Net sales SEK 0 (0); other operating income SEK 19.1m (11.7m); loss after tax SEK -26.9m (-135.5m); EPS SEK -0.04 (-0.39).

• Cash flow from operating activities: Q4 SEK -6.4m (-2.0m); full year SEK -27.9m (-25.5m).

• Cash and cash equivalents at year-end SEK 15.7m (13.3m).

Outlook and guidance

• Pre-validation study results for Psyros expected in Q1 2025; full clinical performance study planned for 2025.

• Anticipates intensified partner interest following study results and continued progress toward commercial launch.